BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines

January 18, 2024

https://www.globenewswire.com/news-release/2024/01/18/2811408/0/en/BridgeBio-Pharma-Secures-up-to-1-25-Billion-of-Capital-from-Blue-Owl-and-CPP-Investments-to-Accelerate-the-Development-and-Launch-of-Genetic-Medicines.html

– The raise includes $500 million in cash from Blue Owl and CPP Investments in exchange for a 5% royalty on future global net sales of acoramidis

– The raise also includes a $450 million credit facility from Blue Owl that refinances existing senior secured credit, extending maturity from 2026 to 2029 subject to certain conditions

Read more at globenewswire.com

Related news for (BBIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.